| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 Readout example | Rezdiffra (Resmetirom) F4/cirrhotic NASH | Phase 3 | — | Small Molecules | Digestive System | ||
Phase 3 Readout example | Rezdiffra (Resmetirom) F4/cirrhotic NASH | Phase 3 | — | Small Molecules | Digestive System | ||
Phase 3 Readout example | Rezdiffra (Resmetirom) F4/cirrhotic NASH | Phase 3 | — | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
Madrigal Pharmaceuticals, Inc.$514.39
-22.56 (-4.2%)
C 47Pipeline Score Overvalued Pharma · Commercial
Market Cap
11.93 B
EPS
-12.80
P/E Ratio
-
Value Trade
126.11 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
311.34 M
R&D Expenses
108.69 M
Operating CF
-167.44 M
Total Assets
1.23 B
Total Liabilities
683.87 M
Equity
543.45 M
D/E Ratio
12,345
-4.31 %
Week
-2.71 %
1 Month
18.91 %
3 Month
-4.71 %
6 Month
300.88 %
5 Year
47.94 %
All Time
Cash Data
Cash Position
812.77 M
Monthly Burn
55.81 M
Runway
12.9 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
303.74 K
52 Week Range
265 - 615
% held by Insiders
5.95 %
% held by Institutions
105.18 %
Enterprise Value
11.46 B
Total Shares
23.06 M
Short %
17.44 %
Float Shares
16.53 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C47
Pipeline Score $2.4B
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.7x
rNPV / MCap Top 72%
Mid Cap (rank 254 of 905)
Percentile RankMadrigal Pharmaceuticals, Inc. carries a moderate pipeline score (47/100), with $2.8B risk-adjusted pipeline value, led by Resmetirom in Non-Alcoholic Fatty Liver Disease (Phase 3), across $86B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resmetirom Small molecule | Non-Alcoholic Fatty Liver Disease | Phase 3 | NCT04951219 | 53% | $2.4B | ACTIVE NOT_RECRUITING | 2,153 | AVERAGE | B (61) | Apr 1, 2027 | LOW_RISK | MEDIUM May 28, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Rezdiffra | metabolic dysfunction-associated steatohepatitis (MASH) | Phase 3 | 2026-05-27 | |||
Rezdiffra | metabolic dysfunction-associated steatohepatitis (MASH) | Phase 3 | 2026-05-27 | |||
Rezdiffra | metabolic dysfunction-associated steatohepatitis (MASH) | Phase 3 | 2026-05-27 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MDGL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MDGL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDGL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDGL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MDGL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MDGL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals recently announced the granting of inducement equity awards to 20 new non-executive employees as part of its 2025 Inducement Plan. The grants were approved by the independent Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4). This initiative aims to incentivize new hires, providing them with restricted stock units that vest over four years, contingent upon continued employment. Madrigal is known for its focus on developing therapeutics for MASH, including its FDA-approved medication, Rezdiffra.
Read more →MDGLMadrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
Madrigal Pharmaceuticals will participate in the 47th Annual Global Goldman Sachs Health Care Conference on June 10, 2026. The event will feature a live webcast of the presentation, which will be accessible through their Investor Relations page. Madrigal's lead product, Rezdiffra, is approved for treating MASH, and a Phase 3 trial is ongoing for compensated MASH cirrhosis.
Read more →MDGLMadrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
Madrigal Pharmaceuticals presented new data at the EASL Congress 2026, highlighting the efficacy of Rezdiffra in reducing cardiovascular and liver-related risks in patients with metabolic dysfunction-associated steatohepatitis (MASH). The Phase 3 MAESTRO program data showed significant improvements in lipid profiles and liver stiffness. The findings underscore Rezdiffra's potential as a foundational therapy for MASH, particularly in patients with cirrhosis.
Read more →MDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - May 21, 2026
Madrigal Pharmaceuticals announced the granting of equity inducement awards to 15 new non-executive employees as part of its 2025 Inducement Plan. The awards, totaling 5,308 time-based restricted stock units, were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4). This initiative aims to enhance recruitment efforts for the company, which focuses on treatments for metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
Madrigal Pharmaceuticals will present new data on Rezdiffra at the EASL Congress 2026. The data includes improvements in lipid profiles and risk scores for cardiovascular and portal hypertension in patients with MASH. The findings support Rezdiffra's integration into clinical practice as a key treatment for metabolic dysfunction-associated steatohepatitis.
Read more →MDGLDocument Madrigal Pharmaceuticals Reports First -Quarter 2026 Financial Results and Provides Corporate Updates First-quarter 2026 Rezdiffra (resmetirom) net sales of $311.3 million, representing year-over-year growth of
Madrigal Pharmaceuticals reported strong financial results for Q1 2026, with Rezdiffra's net sales reaching $311.3 million, reflecting a significant year-over-year growth of 127%. The company announced an expansion of its clinical pipeline by acquiring a licensing agreement for a new siRNA asset aimed at the PNPLA3 mutation related to metabolic dysfunction-associated steatohepatitis (MASH). Despite the growth in revenues and patient adoption, Madrigal faces financial challenges with rising operating costs resulting in a net loss of $94.4 million for the quarter. Overall, the company is well-positioned for continued growth in 2026.
Read more →MDGLMadrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals reported a strong first quarter for 2026, with Rezdiffra achieving blockbuster sales of $311.3 million, a 127% increase year-over-year. The company also announced a global licensing agreement for a clinical-stage siRNA asset targeting the PNPLA3 gene, enhancing its pipeline for treating metabolic dysfunction-associated steatohepatitis (MASH). Despite a net loss of $94.4 million, Madrigal's cash reserves remain robust at $817.9 million, positioning the company for continued growth.
Read more →MDGLMadrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
Madrigal Pharmaceuticals has secured an exclusive global license for ARO-PNPLA3, a clinical-stage siRNA targeting the PNPLA3 gene, which is crucial for treating metabolic dysfunction-associated steatohepatitis (MASH). The Phase 1 trials demonstrated a 46% reduction in liver fat among homozygous patients, indicating a promising precision medicine approach. Madrigal plans to integrate this asset into its existing pipeline, which includes over 10 programs.
Read more →MDGLMadrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
Madrigal Pharmaceuticals will announce its first-quarter 2026 financial results on May 6, 2026, before U.S. markets open. Following this, a live webcast will be held at 8 a.m. Eastern Time to discuss the financial and operational outcomes. The webcast will be accessible on their Investor Relations page.
Read more →MDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - April 7, 2026
Madrigal Pharmaceuticals has granted equity inducement awards to 20 new non-executive employees under its 2025 Inducement Plan. The awards, totaling 8,079 time-based restricted stock units, were approved by the independent Compensation Committee and are intended to incentivize new hires. This move aligns with Madrigal's focus on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - March 19, 2026
Madrigal Pharmaceuticals announced the granting of equity inducement awards to seven new non-executive employees under its 2025 Inducement Plan. The awards, totaling 1,739 time-based restricted stock units, were approved by the independent Compensation Committee and aim to attract talent to the company. This move reflects Madrigal's commitment to its growth and the ongoing development of its therapeutic solutions for metabolic dysfunction-associated steatohepatitis.
Read more →MDGLMadrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Madrigal Pharmaceuticals will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The event will feature a live webcast of the presentation, with a replay available afterward. Madrigal is known for its innovative treatment, Rezdiffra, which targets metabolic dysfunction-associated steatohepatitis (MASH). The company is currently conducting a Phase 3 trial for Rezdiffra in patients with compensated MASH cirrhosis.
Read more →MDGLMadrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
Madrigal Pharmaceuticals reported strong financial results for the fourth quarter and full year of 2025, with Rezdiffra net sales reaching $958.4 million. The company has expanded its MASH pipeline, now including over 10 programs, and has secured a $500 million credit facility to support further development. Madrigal also launched Rezdiffra in Germany after receiving EC conditional authorization, marking it as the only therapy approved for MASH in the EU. Despite increased operating expenses, the company anticipates robust sales growth in 2026, reflecting confidence in ongoing market potential.
Read more →MDGLDocument Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results Fourth-quarter and full-year 2025 Rezdiffra (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of ye
Madrigal Pharmaceuticals reported substantial financial results for the fourth quarter and full year of 2025, with net sales of its drug Rezdiffra reaching $958.4 million. The company has expanded its pipeline to over 10 programs and secured a significant credit facility to advance its initiatives in the metabolic dysfunction-associated steatohepatitis (MASH) space. CEO Bill Sibold highlighted strong growth potential for 2026 due to broadening market access and rising disease awareness. While operating expenses increased sharply, the company's strategic moves position it favorably in the MASH treatment landscape.
Read more →MDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - February 17, 2026
Madrigal Pharmaceuticals announced the granting of equity inducement awards to five new non-executive employees under its 2025 Inducement Plan. These awards, totaling 2,749 restricted stock units, are intended to attract talent and are subject to vesting conditions based on continued employment. Madrigal is focused on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
Madrigal Pharmaceuticals has entered an exclusive global licensing agreement with Suzhou Ribo Life Science for six preclinical siRNA programs aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). This expansion of their pipeline is expected to enhance treatment options for MASH patients. The agreement includes an upfront payment and potential milestone payments totaling up to $4.4 billion.
Read more →MDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - February 5, 2026
Madrigal Pharmaceuticals announced the granting of equity inducement awards to 21 new non-executive employees as part of its 2025 Inducement Plan. The awards, totaling 5,861 restricted stock units, were approved by the company's Compensation Committee under Nasdaq Listing Rule 5635(c)(4). These awards aim to incentivize new hires and support the company's focus on treating metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
Madrigal Pharmaceuticals will announce its fourth-quarter and full-year 2025 financial results on February 19, 2026. The announcement will be followed by a live webcast at 8 a.m. Eastern Time, where management will discuss the company's financial and operational performance. Madrigal is known for its innovative treatment for metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - January 22, 2026
Madrigal Pharmaceuticals announced the granting of equity awards to 40 new non-executive employees as part of its 2025 Inducement Plan. The awards, approved by the Compensation Committee, include options to purchase shares and restricted stock units. This initiative aims to attract talent to support the company's focus on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) - January 21, 2026
Madrigal Pharmaceuticals announced the grant of an equity inducement award to Rita Thakkar, the new Chief Accounting Officer, under its 2025 Inducement Plan. The award, approved by the Board of Directors, includes restricted stock units and stock options with specific vesting schedules. This move is part of Madrigal's strategy to attract talent while focusing on treatments for metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
Madrigal Pharmaceuticals has entered into an exclusive global license agreement with Pfizer for ervogastat, a Phase 2 oral DGAT-2 inhibitor aimed at treating metabolic dysfunction-associated steatohepatitis (MASH). The agreement enhances Madrigal's pipeline and aligns with its goal of advancing combination therapies. The company plans to present further details at the upcoming J.P. Morgan Healthcare Conference.
Read more →MDGLMadrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Madrigal Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be accessible via a live broadcast, with a replay available afterward. The company focuses on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH), with its drug Rezdiffra being the first FDA-approved therapy for this condition.
Read more →MDGLMadrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals has announced its participation in three upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Evercore and Piper Sandler Healthcare Conferences. These events will feature live webcasts that allow investors to access presentations remotely. The company is known for its innovative therapeutic Rezdiffra, which is the first FDA and European Commission approved treatment for metabolic dysfunction-associated steatohepatitis (MASH), addressing a significant medical need in this area.
Read more →MDGLMadrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
Madrigal Pharmaceuticals announced positive two-year data from the Phase 3 MAESTRO-NAFLD-1 trial, highlighting the efficacy of Rezdiffra in patients with compensated MASH cirrhosis. The results showed significant improvements in multiple imaging tests and biomarkers, particularly in patients with low platelet counts. The data were presented at the AASLD The Liver Meeting, emphasizing the urgent need for effective therapies in this high-risk population.
Read more →MDGLMadrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals reported strong third-quarter 2025 financial results, highlighting the success of its drug Rezdiffra, which has over 29,500 patients on therapy. The company anticipates continued growth with annualized sales exceeding $1 billion and a significant portion of the target population yet to be treated. Additionally, Madrigal is advancing its pipeline to enhance treatment efficacy for metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal to Present New Data from the Company’s MASH Program at AASLD’s The Liver Meeting 2025
Madrigal Pharmaceuticals will present new data on its drug Rezdiffra at the AASLD The Liver Meeting 2025. The data includes analyses from the Phase 3 MAESTRO-NAFLD-1 trial focusing on patients with compensated MASH cirrhosis. Rezdiffra has shown significant efficacy in improving liver conditions, though it is not approved for cirrhosis treatment yet.
Read more →MDGLMadrigal Pharmaceuticals to Release Third-Quarter 2025 Financial Results and Host Webcast on November 4, 2025
Madrigal Pharmaceuticals, Inc. announced it will release its third-quarter 2025 financial results on November 4, 2025, before U.S. market opening. After the release, the company's management will hold a live webcast to discuss the financial performance and operational updates. Madrigal focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), aiming to address the unmet medical needs in this area.
Read more →MDGLMadrigal Pharmaceuticals to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
Madrigal Pharmaceuticals will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. The event will feature a live webcast of the presentation, which will be accessible through the company's investor relations page. Madrigal is known for its innovative treatment, Rezdiffra, for metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals has announced that its drug Rezdiffra (resmetirom) has received conditional marketing authorization from the European Commission for treating adults with moderate to advanced liver fibrosis associated with metabolic dysfunction-associated steatohepatitis (MASH). This approval makes Rezdiffra the first and only medication authorized for MASH in the European Union. The approval is based on the successful outcomes from the Phase 3 MAESTRO-NASH trial, and Madrigal plans to launch the drug in Germany by the end of 2025. The company emphasizes the high unmet need for effective treatment among MASH patients with significant fibrosis, who are at greater risk for severe liver complications.
Read more →MDGLMadrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced its participation in the Canaccord Genuity 45th Annual Growth Conference, scheduled for August 12, 2025. The company will present its novel therapeutic, Rezdiffra, which is the first FDA-approved medication for treating metabolic dysfunction-associated steatohepatitis (MASH). The event will be webcast live, offering investors and interested parties easy access to the presentation. Following the live event, a replay will also be made available.
Read more →MDGLMadrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals reported strong second-quarter 2025 financial results, with net sales of Rezdiffra totaling $212.8 million. The company secured a new U.S. patent that extends protection for Rezdiffra until February 2045, in addition to entering a global licensing agreement for an oral GLP-1 treatment candidate. Furthermore, a positive opinion from the European Medicines Agency could pave the way for Rezdiffra's approval for MASH in Europe. The company also reported a significant increase in revenue compared to the previous year and highlighted ongoing commitments to advancing its product pipeline.
Read more →MDGLMadrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited License agreement supports Madrigal's pipeline strategy to develop innovative
Madrigal Pharmaceuticals announced an exclusive global license agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral GLP-1 receptor agonist. This collaboration aims to enhance Madrigal's innovative portfolio, particularly in treating metabolic dysfunction-associated steatohepatitis (MASH). The agreement involves an upfront payment of $120 million, with potential milestones reaching up to $2 billion. Clinical development for SYH2086 is expected to begin in the first half of 2026, supporting Madrigal's ongoing strategy to advance its pipeline anchored by Rezdiffra.
Read more →MDGLMadrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
Madrigal Pharmaceuticals, a biopharmaceutical company focused on novel therapies for metabolic dysfunction-associated steatohepatitis (MASH), announced the upcoming release of its second-quarter 2025 financial results on August 5, 2025. Following the announcement, the management will host a live webcast at 8 a.m. Eastern Time to review the financial and operating results. The webcast will be accessible through the company's Investor Relations webpage, allowing participants to connect and engage directly with management.
Read more →MDGLMadrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH Proceeds to primarily support MASH pipeline expansion and to refinance exis
Madrigal Pharmaceuticals has secured a $500 million senior secured credit facility with Blue Owl Capital to support its pipeline development for metabolic dysfunction-associated steatohepatitis (MASH). The financing includes an initial $350 million term loan and a delayed draw term loan facility of up to $150 million, along with an option for additional incremental credit. The funding is intended for strategic business development and to refinance existing debt, positioning Madrigal for growth as it advances its key product, Rezdiffra. The CEO highlighted the importance of this investment in extending the company's leadership in the MASH treatment arena.
Read more →MDGLMadrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
Madrigal Pharmaceuticals announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for a new patent covering Rezdiffra™ (resmetirom). This patent will provide protection for the medication, which is the first FDA-approved treatment for adults with noncirrhotic MASH, until September 2044. The news marks a significant milestone in the company's ongoing strategy to support the drug's commercial success.
Read more →MDGLMadrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals has announced that the CHMP recommended approval of resmetirom (Rezdiffra) for treating adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) that have moderate to advanced liver fibrosis. This recommendation is based on favorable results from the Phase 3 MAESTRO-NASH trial, which demonstrated fibrosis improvement and MASH resolution. If approved by the European Commission, resmetirom would be the first medication approved in the E.U. for MASH, addressing an urgent need for effective therapeutic options in this growing patient population.
Read more →MDGLMadrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will participate in the 46th Annual Global Goldman Sachs Health Care Conference on June 11, 2025. The company focuses on developing treatments for metabolic dysfunction-associated steatohepatitis (MASH). Their lead medication, Rezdiffra, is the first FDA-approved therapy for MASH with moderate to advanced fibrosis. A live webcast of the presentation will be available, along with a replay afterward.
Read more →MDGLMadrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra in patients with compensated MASH cirrhosis. Over two years, significant reductions in liver stiffness and improvements in portal hypertension risk categories were recorded. Notably, 65% of patients with clinically significant portal hypertension at baseline saw their risk classifications improve. The safety profile was consistent with previous studies, indicating a low rate of discontinuation due to adverse events.
Read more →MDGLMadrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates First-quarter 2025 Rezdiffra (resmetirom) net sales of $137.3 million As of
Madrigal Pharmaceuticals reported its first-quarter 2025 financial results, noting net sales of $137.3 million for Rezdiffra, the FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH). The company has successfully treated over 17,000 patients and received positive feedback from healthcare providers regarding patient improvements. Madrigal announced new data from the MAESTRO-NAFLD-1 trial to be presented at the upcoming EASL Congress and has made key executive appointments. Their financial position remained strong with $848.1 million in cash and securities as of March 31, 2025.
Read more →MDGLMadrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress
Madrigal Pharmaceuticals has announced that it will present late-breaking data on resmetirom for compensated MASH cirrhosis at the EASL Congress in May 2025. The two-year data from the Phase 3 MAESTRO-NAFLD-1 trial indicates potential improvements in liver stiffness, fibrosis biomarkers, and portal hypertension risk. The upcoming presentations underline Madrigal's commitment to addressing significant challenges in treating MASH and highlight its preparations for a European marketing authorization application. Approval in Europe is expected mid-2025.
Read more →MDGLMadrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
Madrigal Pharmaceuticals, Inc. will release its first-quarter 2025 financial results on May 1, 2025, prior to the opening of U.S. financial markets. Following this announcement, the company's management will host a live webcast to discuss the financial and operational results. Madrigal is focused on developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), with its medication Rezdiffra being the first FDA-approved treatment for this condition.
Read more →MDGLMadrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
Madrigal Pharmaceuticals has announced a leadership change where co-founder Rebecca Taub, M.D. will become Senior Scientific and Medical Advisor, while David Soergel, M.D. has been appointed as Chief Medical Officer. Dr. Taub is recognized for her foundational role in the company's success, particularly in developing Rezdiffra, the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH). Dr. Soergel, with over 20 years of experience in drug development, is expected to leverage his expertise to enhance Madrigal's growth and pipeline expansion initiatives.
Read more →MDGLMadrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors Fred Craves, Ph.D. to retire from Madrigal s Board of Directors in July 2025 CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals has appointed Dr. Jacqualyn A. Fouse to its Board of Directors, enhancing its leadership team as it focuses on MASH treatments. Dr. Fouse, with over 30 years of experience in the biotech industry, aims to support the company's goals, including the launch of Rezdiffra. Fred Craves, a longstanding board member, will retire in July 2025 after significant contributions to the company. The announcement reflects Madrigal's aspirations for growth and innovation in addressing metabolic liver diseases.
Read more →MDGLMadrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis
Madrigal Pharmaceuticals announced encouraging two-year data from the MAESTRO-NAFLD-1 trial, showing that patients with compensated MASH cirrhosis treated with Rezdiffra (resmetirom) achieved a mean 6.7 kPa reduction in liver stiffness, the largest reported in this patient population. Additionally, 51% of patients showed improvement, indicating potential benefits in reducing progression to end-stage liver disease. The company plans to discuss these topline results in an upcoming financial results conference call. Despite the positive outcomes, it is reiterated that Rezdiffra is not yet approved for treating patients with compensated MASH cirrhosis until further validation through ongoing trials.
Read more →MDGLMadrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis F
Madrigal Pharmaceuticals reported its fourth-quarter and full-year 2024 financial results, highlighting the success of its FDA-approved drug, Rezdiffra. The company presented two-year data from its Phase 3 MAESTRO-NAFLD-1 trial, indicating ongoing benefits in improving MASH fibrosis markers in patients with compensated MASH cirrhosis. The CEO expressed optimism about Madrigal's position in the MASH community and future performance. The approval of Rezdiffra offers hope for patients in a market with currently no approved therapies for this high-risk condition.
Read more →MDGLMadrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced its participation in the 45th Annual TD Cowen Health Care Conference scheduled for March 4, 2025. The presentation will be accessible via live webcast and will include a replay option afterward. Madrigal focuses on innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), with its leading therapeutic candidate, Rezdiffra, aimed at addressing this liver disease.
Read more →MDGLMadrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
Madrigal Pharmaceuticals, Inc. has announced it will release its fourth-quarter and full-year 2024 financial results on February 26, 2025. Alongside the financial report, the company's management will host a live webcast to discuss the results at 8 a.m. Eastern Time. The webcast will be accessible through the Investor Relations section of the Madrigal Pharmaceuticals website and will also be available for review afterward. Madrigal is known for its development of therapies targeting metabolic dysfunction-associated steatohepatitis (MASH).
Read more →MDGLMadrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra Preliminary fourth-quarter and full-year 2024 Rezdiffra (resmetirom) net sales ra
Madrigal Pharmaceuticals announced preliminary financial results for the fourth quarter and full year of 2024, reporting positive net sales for Rezdiffra, its treatment for metabolic dysfunction-associated steatohepatitis (MASH). The drug has received FDA approval, and over 11,800 patients are currently receiving therapy. The company is preparing for potential European expansion in 2025 and is optimistic about the outcomes of ongoing clinical trials. However, there are challenges associated with a commercial launch due to lack of experience and potential regulatory obstacles.
Read more →MDGLMadrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
Madrigal Pharmaceuticals announced preliminary fourth-quarter and full-year 2024 financial results, revealing Rezdiffra net sales ranging from $100 million to $180 million. More than 11,800 patients are now being treated with Rezdiffra, which received FDA approval as the first and only therapy for metabolic dysfunction-associated steatohepatitis (MASH). The company is also gearing up for European market entry expected in the second half of 2025. CEO Bill Sibold highlighted the ongoing need for effective MASH treatments, especially as the disease is projected to become the leading cause for liver transplants in the U.S.
Read more →MDGLMadrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Madrigal Pharmaceuticals, Inc. has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 15, 2025. The presentation, which will be accessible via webcast, is expected to highlight the company's innovative approaches to treating metabolic dysfunction-associated steatohepatitis (MASH). Madrigal's medication, Rezdiffra, is specifically designed to tackle the critical aspects of this liver disease, showcasing the company's commitment to addressing significant medical needs in this area.
Read more →MDGLMadrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
Madrigal Pharmaceuticals, Inc. has announced its participation in three upcoming investor conferences: the UBS Global Healthcare Conference, the Evercore HealthCONx Conference, and the Piper Sandler Healthcare Conference. Presentations at these events will include live webcasts that will be accessible on the company's Investor Relations Events page. This participation underscores Madrigal's efforts to engage with investors while highlighting its focus on treating nonalcoholic steatohepatitis (NASH) using its medication, Rezdiffra.
Read more →MDGLMadrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates Third-quarter 2024 net sales of $62.2 million Rezdiffra (resmetirom) coverage goal achieved early, with more than 80 pe
Madrigal Pharmaceuticals has reported its third-quarter 2024 financial results, highlighting net sales of $62.2 million, primarily driven by the successful launch of its treatment, Rezdiffra. The company is seeing growing adoption among prescribers and broader payer coverage, indicating a positive reception in the market. Additionally, Madrigal has completed enrollment in a key clinical outcomes study for patients with compensated NASH/MASH cirrhosis, which could pave the way for full approval of Rezdiffra. Despite these successes, the company acknowledges potential regulatory risks and challenges associated with commercial launch and clinical studies.
Read more →MDGLMadrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting
Madrigal Pharmaceuticals announced it will present multiple abstracts regarding Rezdiffra (resmetirom) at the upcoming AASLD Liver Meeting from November 15-19, 2024. This presentation marks the first AASLD meeting since the approval of Rezdiffra, which is the first approved treatment for nonalcoholic steatohepatitis (NASH). The company aims to share clinical developments from their MAESTRO-NASH trial, emphasizing Rezdiffra's role as a foundational therapy for NASH with moderate to advanced fibrosis. The need for advancing patient care is highlighted given NASH's serious health implications, including its status as a leading cause of liver transplants in the U.S.
Read more →MDGLMadrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis
Madrigal Pharmaceuticals has announced the completion of patient enrollment for its Phase 3 MAESTRO-NASH OUTCOMES trial, which aims to evaluate the efficacy of resmetirom in treating patients with compensated NASH cirrhosis. This is a significant milestone as it positions resmetirom to potentially be the first approved treatment for this condition. Additionally, positive results from the trial could support the full approval of Rezdiffra in treating noncirrhotic NASH. The trial is crucial for addressing the critical need for effective therapies in this area of liver disease.
Read more →MDGLMadrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
Madrigal Pharmaceuticals, Inc. has announced that it will release its third-quarter 2024 financial results on October 31, 2024. Following this release, the company's management will host a live webcast at 8 a.m. Eastern Time to discuss the financial and operating results. Participants are encouraged to register beforehand to ensure connection. Madrigal is known for its development of novel therapeutics for nonalcoholic steatohepatitis (NASH).
Read more →MDGLMadrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced its participation in the upcoming H.C. Wainwright 8th Annual MASH Virtual Investor Conference scheduled for October 7, 2024. The event will feature a fireside chat that will be webcast live, enhancing investor engagement. Madrigal is known for its innovative treatments targeting nonalcoholic steatohepatitis (NASH), addressing a critical unmet need in liver diseases.
Read more →MDGLMadrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development
Madrigal Pharmaceuticals has appointed Dr. Michael R. Charlton as Senior Vice President of Clinical Development, effective October 1, 2024. Dr. Charlton brings over 30 years of experience in hepatology and has previously held notable positions at institutions including the Mayo Clinic. His appointment is expected to bolster Madrigal's ongoing efforts in tackling nonalcoholic steatohepatitis (NASH) and leverage his insights to further enhance their R&D initiatives. Madrigal's Rezdiffra therapy aims to address significant unmet needs in treating NASH, particularly among patients with advanced liver fibrosis.
Read more →MDGLMadrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)
Madrigal Pharmaceuticals announced that their drug Rezdiffra has shown positive health-related quality of life results from the Phase 3 MAESTRO-NASH trial. The published findings indicate that patients with moderate to advanced fibrosis experienced significant improvements in various quality of life domains, including emotional well-being and health distress. The results highlight Rezdiffra's strong tolerability profile and its effectiveness as the first FDA-approved treatment for NASH. Ongoing confirmatory trials are expected to further validate these findings.
Read more →MDGLMadrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Madrigal Pharmaceuticals, Inc. will participate in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference, scheduled for September 5, 2024. The company aims to showcase its advancements in developing therapies for nonalcoholic steatohepatitis (NASH). Attendees will be able to access a live webcast of the presentation, with a replay available afterward. This conference highlights Madrigal's commitment to addressing significant medical needs within the liver disease space.
Read more →MDGLMadrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates Second-quarter 2024 net sales of $14.6 million Rezdiffra (resmetirom) coverage in place for more than 50 percent of co
Madrigal Pharmaceuticals has reported its second-quarter 2024 financial results, highlighting a strong launch of its product Rezdiffra for nonalcoholic steatohepatitis (NASH). The CEO noted high demand from physicians and patients, supported by favorable payer coverage. Recent data indicates Rezdiffra's substantial efficacy in managing liver stiffness, positioning it as a primary treatment for NASH. The company plans to expand its market presence in Europe upon receiving regulatory approval.
Read more →MDGLMadrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
Madrigal Pharmaceuticals has announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Kelley brings over 20 years of diverse healthcare legal and compliance experience, having served in various roles at Sanofi and Boston Scientific. CEO Bill Sibold emphasized her leadership qualities and the vital role she played in guiding Madrigal through growth. Kelley expressed enthusiasm for contributing to Madrigal's goal of delivering groundbreaking therapies for nonalcoholic steatohepatitis (NASH).
Read more →MDGLMadrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
Madrigal Pharmaceuticals, Inc. plans to announce its second-quarter 2024 financial results on August 7, 2024, before U.S. market openings. Following the release, the company will host a live webcast at 8 a.m. Eastern Time to discuss financial and operational outcomes. Relevant stakeholders can access the webcast through the Investor Relations section of the Madrigal website, with recommendations to register in advance for participation.
Read more →MDGLMadrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
Madrigal Pharmaceuticals presented new data at the EASL Congress regarding their Phase 3 MAESTRO-NASH study of Rezdiffra (resmetirom). The data indicate that Rezdiffra significantly improved fibrotic features that predict progression to more severe liver disease. Moreover, 91% of patients showed improvement or stability in liver stiffness over three years, and health-related quality of life scores improved in treated patients. The study also included initial findings on Rezdiffra's effectiveness in patients with metabolic dysfunction and alcohol-associated liver disease.
Read more →MDGLMadrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Madrigal Pharmaceuticals, Inc. has announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 11, 2024. The presentation will take place at 8:40 A.M. ET and will be available via a live webcast. The company is known for its focus on developing novel therapeutics for nonalcoholic steatohepatitis (NASH), particularly its drug Rezdiffra (resmetirom), which aims to address key issues related to this liver disease. A replay of the webcast will be accessible after the event, further providing opportunities for investor engagement.
Read more →MDGLMadrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
Madrigal Pharmaceuticals announced it will present multiple data analyses on its drug Rezdiffra at the upcoming EASL Congress in Milan from June 5-8, 2024. The data presentations will emphasize Rezdiffra's status as a foundational therapy for nonalcoholic steatohepatitis (NASH), showcasing results from the MAESTRO Phase 3 program including new findings on quality of life and the drug's efficacy. The event aims to highlight the critical health impact of uncontrolled NASH on patients and healthcare systems.
Read more →MDGLMadrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates On
Madrigal Pharmaceuticals reported its first-quarter 2024 financial results and announced the launch of Rezdiffra, an FDA-approved therapy for nonalcoholic steatohepatitis (NASH). The CEO highlighted the drug's potential as a foundational treatment and expressed optimism regarding initial reactions from the medical community. The company aims to target around 315,000 patients with moderate to advanced liver fibrosis caused by NASH. Despite the promising launch, Madrigal faces challenges associated with securing regulatory approvals and executing its commercial strategy.
Read more →MDGLMadrigal Statement on the Passing of Dr. Stephen Harrison
Madrigal has expressed deep sorrow over the passing of Dr. Stephen Harrison, a valued colleague and friend. Dr. Harrison was recognized for his tireless efforts to improve the lives of patients with nonalcoholic steatohepatitis (NASH) and left a profound impact on the field. His contributions and collaborations with various sectors will continue to influence NASH research for many years. Madrigal honors his legacy and the joy he brought to those around him.
Read more →MDGLMadrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Madrigal Pharmaceuticals, Inc. will announce its first-quarter 2024 financial results on May 7, 2024, before the U.S. markets open. Following this announcement, the company's management will host a live webcast at 8 a.m. ET to review the results. The webcast will be accessible through the Investor Relations section of their website, and registration is recommended to ensure timely connection.
Read more →MDGLMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals has granted equity inducement awards to seven new employees as part of its 2023 Inducement Plan. The awards include options to purchase shares and time-based restricted stock units, aiming to support employee retention and acceptance of employment. These grants were made under Nasdaq Listing Rule 5635(c)(4) and are part of the company's continued efforts in addressing nonalcoholic steatohepatitis (NASH). This strategic move reflects the company's commitment to fostering a strong workforce as it advances its therapeutic initiatives.
Read more →MDGLMadrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals has announced that Rezdiffra (resmetirom) is now available in the U.S. for adults with noncirrhotic NASH with moderate to advanced liver fibrosis. This marks the first FDA-approved treatment for NASH, which had previously lacked effective therapeutic options. The company is implementing a specialty pharmacy network and patient support programs to facilitate access to the medication. However, the continued approval of Rezdiffra may depend on the outcomes of ongoing trials confirming its clinical benefits.
Read more →MDGLMadrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
Madrigal Pharmaceuticals announced the pricing of its underwritten public offering, increasing its size to $600 million. The offering consists of 750,000 shares of common stock and pre-funded warrants, aimed at financing the commercial launch of Rezdiffra (resmetirom) and supporting various corporate purposes. The company's gross proceeds are expected to be approximately $600 million, with a closing date anticipated around March 21, 2024, pending customary conditions. Several investment banks are acting as bookrunning managers for the offering.
Read more →MDGLMadrigal Pharmaceuticals Announces Proposed Public Offering
Madrigal Pharmaceuticals, Inc. has announced a proposed public offering of $500 million in shares, primarily intended to support the launch of its investigational drug Rezdiffra and general corporate purposes. The shares will be sold under an effective shelf registration statement, with underwriting managed by several prominent investment firms. This offering reflects Madrigal's aim to enhance its commercial activities and could impact its financial standing significantly. However, the successful completion of the offering is contingent upon market conditions.
Read more →MDGLMadrigal Pharmaceuticals Announces FDA Approval of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis Rezdiffra becomes the
Madrigal Pharmaceuticals has received FDA approval for Rezdiffra (resmetirom) as a treatment for adults with noncirrhotic Nonalcoholic Steatohepatitis (NASH) with moderate to advanced liver fibrosis. This marks the first FDA-approved therapy for this serious condition, following promising results from the Phase 3 MAESTRO-NASH trial. Rezdiffra demonstrated considerable efficacy in improving NASH resolution and fibrosis stage without worsening liver condition. The approval highlights a significant advancement in the management of NASH, with an emphasis on improving patient outcomes through innovative therapies.
Read more →MDGLMadrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
Madrigal Pharmaceuticals has announced that its Marketing Authorization Application for resmetirom, aimed at treating NASH with liver fibrosis, has been validated by the European Medicines Agency (EMA) and is now under evaluation. This follows positive results from the MAESTRO-NASH Phase 3 trial, marking a significant milestone as it is the only trial to achieve both fibrosis reduction and NASH resolution. The resmetirom application is also under review by the FDA with an action date of March 14, 2024. The company aims to serve approximately 315,000 patients diagnosed with significant fibrosis due to NASH.
Read more →MDGLMadrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
Madrigal Pharmaceuticals has appointed Mardi C. Dier as Chief Financial Officer, effective March 11, 2024. Dier has extensive experience in financial leadership within the biopharmaceutical industry, having previously held CFO positions at several companies. Bill Sibold, CEO of Madrigal, expressed confidence in Dier’s capabilities to aid in the company’s growth and the upcoming launch of their lead therapeutic candidate, resmetirom. Dier initially joined Madrigal as a Senior Advisor and will transition smoothly from the current CFO, Alex Howarth.
Read more →MDGLMadrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results Announced appointment of Mardi C. Dier as Chief Financial Officer Anticipates resmetirom to become the f
Madrigal Pharmaceuticals reported its fourth quarter and full year 2023 financial results, highlighting a strong cash position of $634.1 million. The company is preparing for the anticipated March 2024 launch of resmetirom, a therapy targeting nonalcoholic steatohepatitis (NASH) with significant fibrosis. The results included increased operating expenses driven by enhanced R&D efforts and commercialization activities. Despite optimism regarding resmetirom's market potential, Madrigal faces challenges related to rising costs and regulatory uncertainties.
Read more →MDGLMadrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine
Madrigal Pharmaceuticals announced the publication of the MAESTRO-NASH trial results in the New England Journal of Medicine, marking a significant milestone for resmetirom in treating NASH. The trial is notable for achieving both primary endpoints of fibrosis improvement and NASH resolution, underlining the drug's potential to become the first approved therapy for this condition. The FDA has set a PDUFA date of March 14, 2024, for the potential approval of resmetirom. The study's results and ongoing research aim to establish resmetirom as a transformative option for patients with significant fibrosis due to NASH.
Read more →MDGLMadrigal Pharmaceuticals Announces Additions to Its Leadership Team
Madrigal Pharmaceuticals has announced three key additions to its leadership team, aiming to bolster its efforts as it prepares for the first-to-market launch of its drug resmetirom for nonalcoholic steatohepatitis (NASH). Mark Barrett joins as Chief Business Officer, while Clint Wallace and Tina Ventura take on roles as Chief Human Resources Officer and Chief Investor Relations Officer, respectively. These new leaders are expected to play critical roles in Madrigal's next phase of growth, leveraging their extensive experience in the biopharmaceutical industry.
Read more →MDGLForward Looking Statements Madrigal Pharmaceuticals This presentation includes "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are ba
Madrigal Pharmaceuticals has highlighted the potential of its investigational therapy, Resmetirom, as a leading candidate for treating NASH patients with significant fibrosis. The company's forward-looking statements emphasize the possibility of achieving pivotal FDA approvals and addressing critical patient needs in this area. However, they acknowledge the accompanying risks including regulatory delays and clinical study challenges. With promising Phase 3 results reported, Madrigal aims to leverage its opportunities in a market with significant unmet medical need.
Read more →MDGLMadrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
Madrigal Pharmaceuticals presented five abstracts at the NASH-TAG Annual Conference that underline the serious clinical implications of uncontrolled nonalcoholic steatohepatitis (NASH). Analysis conducted showed a significant increase in the risk of cirrhosis and other severe outcomes over time for patients with NASH. The findings also suggest that many patients are not receiving adequate specialist care as per recommended guidelines. Additionally, the research points to the potential role of resmetirom in addressing these challenges by targeting the underlying causes of NASH.
Read more →MDGLMadrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company focused on treating nonalcoholic steatohepatitis (NASH), announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 10, 2024. The presentation will be available via webcast, with a recorded version accessible after the event. Madrigal aims to highlight its lead therapy, resmetirom, which is designed to address key factors contributing to NASH.
Read more →MDGLMadrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer
Madrigal Pharmaceuticals has appointed Ronald Filippo as Chief Information Officer, effective immediately. Filippo, who has over 25 years of digital experience, previously served as Senior Vice President Digital at Moderna where he oversaw technology leadership during the COVID-19 vaccine commercialization. His expertise is expected to enhance Madrigal's information technology and AI capabilities during a crucial growth phase, particularly as the company prepares for the launch of its lead candidate, resmetirom, targeting nonalcoholic steatohepatitis (NASH).
Read more →MDGLMadrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer
Madrigal Pharmaceuticals has appointed Carole Huntsman as Chief Commercial Officer, who has a strong background in specialty care and successful product launches. Her previous experience includes directing over 2,600 team members at Sanofi and overseeing significant annual net sales. This leadership change comes as Madrigal prepares for the anticipated U.S. launch of its therapy, resmetirom, targeting nonalcoholic steatohepatitis (NASH). The CEO expressed confidence in Huntsman's ability to build a high-performing team to deliver innovative therapies.
Read more →MDGLMadrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health
Madrigal Pharmaceuticals presented new data from the Phase 3 MAESTRO-NASH trial at the AASLD Liver Meeting, highlighting the broad treatment effects of their investigational therapy, resmetirom, on noninvasive tests for liver health. The findings show over 70% of patients experienced significant reductions in MRI-PDFF, predicting NASH resolution and fibrosis improvement. Additionally, resmetirom demonstrated improvements in liver enzymes and beneficial impacts on LDL cholesterol levels, which are linked to heart disease. The data is pivotal as the company seeks accelerated FDA approval for treating NASH with liver fibrosis.
Read more →MDGLMadrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results Priority Review of resmetirom new drug application underway in the U.S. Bill Sibold appointed Chief Executive Officer o
Madrigal Pharmaceuticals reported its third quarter 2023 financial results and provided corporate updates, focusing on the upcoming launch of resmetirom, a therapy for nonalcoholic steatohepatitis (NASH). With significant financing secured, the company is preparing for a potential approval in March 2024. Upcoming presentations of Phase 3 MAESTRO study data at the AASLD Liver Meeting are expected to showcase positive treatment responses. Despite financial challenges, Madrigal remains committed to addressing the unmet medical need in NASH treatment.
Read more →MDGLMadrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering
Madrigal Pharmaceuticals, Inc. announced the pricing of a public offering of $500 million, consisting of over 1.2 million shares of common stock and pre-funded warrants. The proceeds will be directed towards clinical and commercial preparations for the launch of resmetirom, intended for treating nonalcoholic steatohepatitis (NASH). The offering, led by several major financial institutions, is expected to close on October 3, 2023, subject to customary conditions. Madrigal has also granted underwriters an option to purchase additional shares, potentially increasing the total raised amount.
Read more →MDGLMadrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis CONSHOHOCKEN, PA
Madrigal Pharmaceuticals announced the FDA's acceptance of its New Drug Application for resmetirom, aimed at treating adults with nonalcoholic steatohepatitis (NASH) with liver fibrosis. This application has been granted Priority Review, allowing for a faster review timeline and a target action date of March 14, 2024. Resmetirom aims to address a significant healthcare need and has been supported by extensive clinical studies indicating its safety and efficacy. The absence of an advisory committee meeting suggests confidence in the NDA process.
Read more →MDGLMadrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer
Madrigal Pharmaceuticals has appointed Bill Sibold as its new Chief Executive Officer, succeeding Paul Friedman, who will continue to serve on the Board. Sibold brings substantial experience from Sanofi, where he led significant growth and launched key therapies. His leadership is expected to drive Madrigal through its next growth phase, particularly as the company focuses on developing innovative treatments for nonalcoholic steatohepatitis (NASH). The company aims to build upon its legacy and deliver solutions for significant unmet medical needs in the healthcare community.
Read more →MDGLMadrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug Administration NASH disease education and ma
Madrigal Pharmaceuticals, Inc. has reported its second-quarter financial results and significant updates regarding its NASH therapeutic drug, resmetirom. The company has submitted a new drug application (NDA) for resmetirom to the FDA, marking an important step towards potential approval. Their Phase 3 MAESTRO clinical trials have shown promising safety and efficacy results, and Madrigal is preparing for a possible launch while enhancing disease education efforts. Financially, the company has experienced operational cash usage but has also raised capital to support ongoing development activities.
Read more →MDGLMadrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis CONSHOHOCKEN, PA
Madrigal Pharmaceuticals has completed its New Drug Application (NDA) submission for resmetirom, targeting accelerated approval for treating nonalcoholic steatohepatitis (NASH) with liver fibrosis. This submission is based on several successful clinical trials, including the pivotal MAESTRO-NASH trial which showed significant improvements in liver health markers. The FDA has granted Breakthrough Therapy designation to resmetirom, emphasizing its potential as the first approved treatment for this serious condition. Despite its positive trajectory, the lack of current FDA-approved options for NASH highlights the urgency of the drug's development.
Read more →MDGLMadrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis Madrigal expects to complete full submiss
Madrigal Pharmaceuticals has begun a rolling submission of a New Drug Application (NDA) to the U.S. FDA for accelerated approval of resmetirom, aimed at treating nonalcoholic steatohepatitis (NASH) with liver fibrosis. The company has submitted the majority of the NDA and is expecting to finalize the submission in July 2023. Resmetirom was previously granted Breakthrough Therapy designation, highlighting its potential significance, and positive trial results reinforce its promise as an effective treatment for NASH. Madrigal's CEO expressed commitment to fulfilling patient needs due to the lack of existing approved treatments for NASH.
Read more →MDGLMadrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
Madrigal Pharmaceuticals presented Phase 3 MAESTRO-NASH trial data at the EASL Congress, confirming significant efficacy of resmetirom for treating nonalcoholic steatohepatitis (NASH). The results indicated achievement of primary endpoints, enhanced by noninvasive imaging and biomarker data. Resmetirom demonstrated a favorable safety profile, despite some reported gastrointestinal side effects. The company plans an investor event to discuss these findings further.
Read more →MDGLMadrigal Pharmaceuticals Supports International NASH Day on June 8
Madrigal Pharmaceuticals announced its support for the sixth International NASH Day, set for June 8, 2023. The initiative, led by the Global Liver Institute, aims to raise awareness about nonalcoholic fatty liver disease (NAFLD) and its advanced form, NASH. Madrigal's CEO and CMO emphasized their commitment to collaborating with patient advocates and improving disease education through community partnerships and a new campaign targeted at patients. The event highlights the critical need for increased awareness and education surrounding NASH.
Read more →MDGLMadrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
Madrigal Pharmaceuticals, a clinical-stage biopharma company focusing on therapeutics for NASH, announced its participation in two significant investor conferences. The company will partake in fireside chats at the Jefferies Healthcare Conference and the Goldman Sachs Global Healthcare Conference in June 2023. These events aim to enhance investor engagement and showcase Madrigal's lead candidate, resmetirom, which targets unmet needs in liver disease. Webcasts of the discussions will be available for replay on the company's website afterward.
Read more →MDGLMadrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
CONSHOHOCKEN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside ch
Read more →MDGLMadrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results Resmetirom new drug application (NDA) filing on track for Q2 2023 Resmetirom has received Breakthrough Therapy designat
Madrigal Pharmaceuticals announced progress in its clinical developments, particularly relating to its investigational drug resmetirom for treating nonalcoholic steatohepatitis (NASH). The company aims to file a New Drug Application (NDA) for resmetirom in Q2 2023 and has received Breakthrough Therapy designation. In their recent financial results, Madrigal reported an increase in operating expenses and a decrease in cash reserves compared to the prior year, reflecting ongoing investments in clinical trials and corporate preparations. Upcoming presentations at notable scientific meetings are also anticipated to share results from their studies.
Read more →MDGLMadrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial
CONSHOHOCKEN, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that resmetirom has received Breakthrough Therapy de
Read more →MDGLMadrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom
Madrigal Pharmaceuticals has provided corporate updates and announced its financial results for 2022, highlighting the positive outcomes from the Phase 3 MAESTRO-NASH study. These results position the company favorably for regulatory filings and market preparation for resmetirom, currently pursued as a treatment for nonalcoholic steatohepatitis (NASH). The company's financial status has improved, with $358.8 million in cash and marketable securities, enabling ongoing and future clinical trial activities. Madrigal remains on track to file its New Drug Application in the first half of 2023 and launch market development initiatives.
Read more →MDGLMadrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trial A supportive analysis using consensus reads of digitized biopsy images by the central pathologists replicated the positive p
Read more →MDGLMadrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program $259 Million in Equity Securities Sales and $50 Million in Additional Debt Financing Capacity Madrigal intends to submit
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program CONSHOHOCKEN, PA, December 21, 2022 Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that it has raised $259 million in gross equity (or $255 million in net proceeds)
Read more →MDGLMadrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses, 80 mg and 100 mg, relative to placebo NASH resolution (ballooning of 0, inf
Read more →MDGLMadrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th
CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), plans to announce topline results from the Phase 3 MAESTRO-NASH stud
Read more →MDGLMadrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results Two resmetirom oral abstracts to be presented at the AASLD Liver Meeting : Phase 3
Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results CONSHOHOCKEN, PA, November 3, 2022 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel t
Read more →MDGLMadrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
CONSHOHOCKEN, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in a fireside
Read more →MDGLMadrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis
CONSHOHOCKEN, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced initiation of the “MAESTRO-NASH Outcomes” study of re
Read more →MDGLMadrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results Madrigal remains on track to announce topline data from the Phase 3 MAESTRO-NASH biopsy study in the fourt
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results CONSHOHOCKEN, PA, August 4, 2022 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoho
Read more →MDGLMadrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
Late-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce liver fat, fibrosis measures on FibroScan and MRE, and liver enzymes, as well as multiple atherogenic lipids In NASH pati
Read more →MDGLMadrigal Pharmaceuticals Supports International NASH Day on June 9
CONSHOHOCKEN, Pa., June 06, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today announced its support for the fifth International NASH Day, ta
Read more →MDGLMadrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results MAESTRO-NAFLD-1 late-breaker and three other Madrigal abstracts accepted for oral presentation at the EASL
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial host conference call at 8:00 AM ET, May 9th, 2022 CONSHOHOCKEN, PA, May 9, 2022 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pur
Read more →MDGLMadrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
CONSHOHOCKEN, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), will report its first quarter 2022 financial results on Monday, Ma
Read more →MDGLMadrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
CONSHOHOCKEN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in the 32nd A
Read more →MDGLMadrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results CONSHOHOCKEN, PA
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial CONSHOHOCKEN, PA, February 24, 2022 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for n
Read more →MDGLMadrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st
CONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmeti
Read more →MDGLMadrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
CONSHOHOCKEN, Pa., Dec. 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today provides an update on MAESTRO-NAFLD-1, its 52-week Phase 3 multi-center, double-blind, randomized, placebo-controlled study of resmetirom in patients with non-alcoholic fatty l
Read more →MDGLMadrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepati
Read more →MDGLMadrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results Several abstracts with data from the open-label arm of the Phase 3 MAESTRO-NAFLD-1 study accepted for presentation at AA
Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results Several abstracts with data from the open-label arm of the Phase 3 MAESTRO-NAFLD-1 study accepted for presentation at AASLD s upcoming The Liver Meeting 2021 CONSHOHOCKEN, PA, N
Read more →MDGLMadrigal Pharmaceuticals Announces Support of Fatty Liver Foundation’s Screening Fund to Improve Diagnosis and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)
CONSHOHOCKEN, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announces its support of the Fatty Liver Foundation, the leading patient advocacy organiza
Read more →MDGLMadrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update
Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update Conshohocken, PA., August 5, 2021 (GLOBE NEWSWIRE) Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of
Read more →MDGLMadrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study
CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension study of MAESTRO-NAFLD-1, named MAESTRO-NAFLD-1-Open Label Extension (OLE) (NCT0495
Read more →MDGLMadrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom
CONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NASH. Serial liver biopsy and safety data from patients enrolled in MAESTRO-NASH c
Read more →MDGLMadrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021
Use of non-invasive measurements demonstrated that resmetirom: was safe and well-tolerated at 100 mg per day in non-cirrhotic NASH patients treated for 52 weeks; provided rapid and sustained reductions, measured by imaging and/or blood levels, of hepatic fat, fibrosis, liver ce
Read more →MDGLMadrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference
WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohep
Read more →MDGLAlex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer
Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer WEST CONSHOHOCKEN, Pa., May 18, 2021 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with hi
Read more →MDGLMadrigal Pharmaceuticals to Present at RBC Capital Markets Virtual 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 8:00 a.m. ET
WEST CONSHOHOCKEN, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohep
Read more →MDGLMadrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights
Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights CONSHOHOCKEN, Pa., May 6, 2021 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first quarter 2021 financial results and highlights. We expect several important events for Madr
Read more →MDGLMadrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights
Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights WEST CONSHOHOCKEN, Pa., February 25, 2021 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights. W
Read more →MDGLMadrigal Pharmaceuticals Highlights Presentations at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting November 13, 2020, Including NASH Expert Insights on the Ongoing Open Label Arm of Resmetirom 52-Week Phase 3 MAESTRO-NAFLD-1 Trial
Dr. Stephen Harrison will present Resmetirom for the Treatment of NASH: Early Data from the Phase 3 MAESTRO Clinical Trials | The Liver Meeting Digital Experience™, AASLD Product Theater on Friday, November 13, 2020, at 4:30 PM ET. In the 100 mg open label arm of MAESTRO-NAFLD:
Read more →MDGLMadrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter
Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights CONSHOHOCKEN, Pa., November 5, 2020 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enroll
Read more →MDGLMadrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in patients with presumed NASH who are diagnosed using non-invasive assessments. The
Read more →MDGLMadrigal Pharmaceuticals Announces Three Abstracts Accepted by The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting in November 2020, including Positive Data from Ongoing Open Label Arm of Resmetirom 52 Week Phase 3 MAESTRO-NAFLD-1 Trial
High accuracy in predicting advanced NASH fibrosis (F2-F3) in Phase 3 MAESTRO-NASH study using clinical characteristics and simple, readily available non-invasive imaging and biomarkers Data from ongoing MAESTRO-NAFLD-1 open label arm confirm robust liver fat reduction on MRI-PD
Read more →MDGLMadrigal Pharmaceuticals Exceeds Target Enrollment in Phase 3 MAESTRO NAFLD-1 Trial
-- Completion of enrollment in MAESTRO-NAFLD-1 will enable reporting of topline 52-week data by the end of next year as planned. -- Madrigal intends to present selected data from ongoing open label arm by the end of 2020 -- Recent presentations at EASL Digital ILC of secondary an
Read more →MDGLMadrigal Pharmaceuticals to Present Secondary Analyses of Data from Phase 2 NASH Study of Resmetirom and Symposium at the Digital International Liver Congress™ 2020
CONSHOHOCKEN, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020, European Association for the Study of the Liver (EASL), secondary analyses of data
Read more →MDGLMadrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals Reports 2020 Second Quarter Financial Results and Highlights CONSHOHOCKEN, Pa., August 6, 2020 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and The Madrigal team and our CRO s are focused on com
Read more →MDGLMadrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals Reports 2020 First Quarter Financial Results and Highlights CONSHOHOCKEN, Pa., May 7, 2020 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2020 financial results and Madrigal continued to make progress toward our clinical
Read more →MDGLMadrigal MAESTRO Phase 3 NASH Trials Continue without Protocol Modifications; New Data Demonstrate that Reductions in Liver Fat Achieved by Resmetirom Predict NASH Resolution and Fibrosis Reduction
-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patient safety and trial integrity during the COVID pandemic. -- Abstracts accepted for oral
Read more →MDGLMadrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights CONSHOHOCKEN, Pa., February 26, 2020 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2019 financial results and highlights: Madrig
Read more →MDGLMadrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease))
-- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized, placebo-controlled study in patients with non-alcoholic steatohepatitis (NASH) and fibrosis, that
Read more →MDGLMadrigal Pharmaceuticals Announces Pricing of Secondary Offering
WEST CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatmen
Read more →MDGLMadrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock
CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of
Read more →MDGLMadrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH)
Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH: demonstrated that resmetirom treatment resulted in statistically significant reduction in hepatic fat measured non-invasively (magnetic resonance imagi
Read more →MDGLMadrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights CONSHOHOCKEN, Pa., November 6, 2019 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and Madrigal continued to execute its clinical develop
Read more →MDGLMadrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights Phase 3 MAESTRO-NASH Program Continues to Progress Jim Daly Added to Board of Directors and Becky Taub Promoted to President of R&D Ma
Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights Phase 3 MAESTRO-NASH Program Continues to Progress Jim Daly Added to Board of Directors and Becky Taub Promoted to President of R&D Madrigal Presentations Selected for the Liver Meeting AASL
Read more →MDGLMadrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development
-- Dr. Taub to present at the 5th Paris NASH Meeting to be held on July 11-12, 2019 -- CONSHOHOCKEN, Pa., July 11, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today the promotion of Rebecca Taub, M.D., to the newly created positon of President
Read more →MDGLMadrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors
CONSHOHOCKEN, Pa., July 02, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Jim Daly has been appointed to the Company’s Board of Directors, as a Class I director, effective as of June 27, 2019. “We are extremely pleased to have an exec
Read more →MDGLMadrigal Pharmaceuticals to Present at Upcoming Investment Conferences
CONSHOHOCKEN, Pa., June 04, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that Paul Friedman, M.D., Chief Executive Officer of Madrigal, and Becky Taub, M.D., CMO and Executive VP, Research & Development of Madrigal will present at the foll
Read more →MDGLMadrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights CONSHOHOCKEN, Pa., May 8, 2019 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2019 financial results and highlights: Madrigal continued to make significant prog
Read more →MDGLMadrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress™ 2019
-- MRI-PDFF response (≥30% reduction in hepatic fat) at 12 weeks correlated with reduction in the ballooning and inflammation components of NAS and was predictive of NASH resolution on liver biopsy at 36 weeks -- -- The data suggest that reduction of hepatic fat is a critical co
Read more →MDGLMadrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
-- Investigator meeting held March 21/22, 2019 -- -- In Phase 2 study resmetirom was statistically significantly superior to placebo in resolving NASH on biopsy, appeared safe and was well-tolerated -- CONSHOHOCKEN, Pa., March 28, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceutica
Read more →MDGLMadrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights CONSHOHOCKEN, Pa., February 27, 2019 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2018 financial results and highlights: Madriga
Read more →MDGLMadrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events CONSHOHOCKEN, Pa., November 6, 2018 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2018 financial results and described upcoming clinica
Read more →MDGLMadrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements Madrigal s MGL-3196 NASH abstract selected for oral presentation in the presidential plenary clinical session o
Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements Madrigal s MGL-3196 NASH abstract selected for oral presentation in the presidential plenary clinical session of The Liver Meeting 2018 during the American Association f
Read more →MDGLMadrigal Pharmaceuticals Prices Public Offering of Common Stock
CONSHOHOCKEN, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and
Read more →MDGLMadrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
CONSHOHOCKEN, Pa., June 05, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and
Read more →MDGLMadrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial Statistically significantly more patients treated with MGL-3196 compared wit
Madrigal s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved a two point reduction
Read more →MDGLMadrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements CONSHOHOCKEN, Pa.
Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements CONSHOHOCKEN, Pa., May 8, 2018 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2018 financial results. During the first quarter, the Compan
Read more →MDGLMadrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196 - MGL-3196 is a first-in-class, oral, once-daily, liver-dir
Madrigal Pharmaceuticals Reports 2017 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Clinical Update on MGL-3196 - MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) -selective agonist
Read more →MDGLMadrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
-- Statistically significant improvement achieved in the reduction of LDL cholesterol (LDL-C) with MGL-3196 compared to placebo, the primary endpoint of this 12-week Phase 2 clinical trial in HeFH patients on maximal statin therapy -- -- Statistically significant results also ac
Read more →MDGLMadrigal Announces Acceptance of MGL-3196 Abstract for a Main Plenary Presentation at The International Liver Congress™ 2018
CONSHOHOCKEN, Pa., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today announced that Week 12 Phase 2 results for MGL-3196, its first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist, will be presented
Read more →MDGLMadrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical Trial
-- Statistically significant improvement in the relative decrease in liver fat in patients treated with MGL-3196 compared with placebo, determined by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) at 12-weeks, the primary end point in this Phase 2 pro
Read more →MDGLMadrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results Top-line results from MGL-3196 Phase 2 clinical trials in NASH and HeFH expected in late 2017 and early 2018, respectively Conshohocken, PA
Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial Results Top-line results from MGL-3196 Phase 2 clinical trials in NASH and HeFH expected in late 2017 and early 2018, respectively Conshohocken, PA November 9, 2017 Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today
Read more →MDGLMadrigal Pharmaceuticals Announces Positive Outcome from Pre-Planned DSMB Safety Review and Completion of Enrollment of Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia
-- Second DSMB review includes data from both Phase 2 studies in NASH and HeFH -- -- Top-line results from NASH expected late 2017 and HeFH early 2018 -- CONSHOHOCKEN, Pa., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today announced that the
Read more →MDGLMadrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results - Completed patient enrollment in Phase 2 clinical study of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, for tre
Madrigal Pharmaceuticals Reports 2017 Second Quarter Financial Results - Completed patient enrollment in Phase 2 clinical study of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, for treatment of NASH - Raised $35 million financing to provide s
Read more →MDGLMadrigal Pharmaceuticals Completes Enrollment in Phase 2 Proof-of-Concept Study with MGL-3196 for Treatment of NASH
-- Primary endpoint is the reduction of liver fat, assessed by MRI-PDFF, at 12 weeks -- -- Company expects to report top-line results by year-end -- CONSHOHOCKEN, Pa., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today announced that it has com
Read more →MDGLNOT FOR IMMEDIATE RELEASE Madrigal Pharmaceuticals Announces $35 Million Private Placement Offering West Conshohocken, PA
NOT FOR IMMEDIATE RELEASE Madrigal Pharmaceuticals Announces $35 Million Private Placement Offering West Conshohocken, PA June 21, 2017 Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that it has entered into a definitive securities purchase agreement with a group
Read more →MDGLMadrigal Pharmaceuticals Announces $35 Million Private Placement Offering
WEST CONSHOHOCKEN, Pa., June 21, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that it has entered into a definitive securities purchase agreement with a group of institutional accredited investors for the private placement offering of appr
Read more →MDGLMadrigal Pharmaceuticals Reports 2017 First Quarter Financial Results - Phase 2 clinical studies of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, are underway in patients with non-alco
Madrigal Pharmaceuticals Reports 2017 First Quarter Financial Results - Phase 2 clinical studies of MGL-3196, a liver-directed thyroid hormone receptor (THR) beta selective agonist, are underway in patients with non-alcoholic steatohepatitis (NASH) and familial hypercholesterole
Read more →MDGLMadrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196 - MGL-3196, a liver -directed thyroid
Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial Results, Reviews Key Corporate Achievements and Provides Update on Lead Clinical-stage Compound, MGL-3196 - MGL-3196, a liver -directed thyroid hormone receptor (THR) beta selective agonist, has the po
Read more →MDGLMadrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)
-- HeFH is the most common dominantly inherited disease, present in up to 1 in 200 people, in which there is a life-long burden of high LDL cholesterol build up requiring aggressive lipid lowering treatment -- -- Primary endpoint is the reduction of LDL cholesterol, with seconda
Read more →MDGLMADRIGAL REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS -Successfully Completed Merger and Transition to Public Company- - Initiated Phase II study in NASH - - Out-licensed non-core asset HSP90 to Tar
MADRIGAL REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS -Successfully Completed Merger and Transition to Public Company- - Initiated Phase II study in NASH - - Out-licensed non-core asset HSP90 to Tarveda Therapeutics - West Conshohocken, PA November 14, 2016 Madrigal Pharmaceu
Read more →MDGLMadrigal Reports Third Quarter 2016 Financial Results
- Successfully Completed Merger and Transition to Public Company - - Initiated Phase II study in NASH - - Out-licensed non-core asset HSP90 to Tarveda Therapeutics - WEST CONSHOHOCKEN, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today re
Read more →MDGLMadrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Non-alcoholic Steatohepatitis (NASH)
-- Study expected to provide proof-of-concept data in NASH for the first liver-directed, thyroid hormone receptor (THR) ß-selective agonist – -- Primary endpoint is the reduction of liver fat, assessed by MRI-PDFF, at 12 weeks, with confirmation of NASH resolution by biopsy at 3
Read more →MDGLMadrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform
- PEN-866 positioned to begin clinical trials in 2017 – - Total potential payments to Madrigal may exceed $249 Million – CONSHOHOCKEN, Pa. and WATERTOWN, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) and Tarveda Therapeutics, Inc. today
Read more →MDGLRichard S. Levy, M. D., Appointed to Madrigal Board of Directors
Richard S. Levy, M. D., Appointed to Madrigal Board of Directors FORT WASHINGTON, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) MADRIGAL PHARMACEUTICALS, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies
Read more →MDGLMadrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company - Newly NASDAQ-listed MDGL focused on the development of novel small-molecule drugs addressing maj
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company - Newly NASDAQ-listed MDGL focused on the development of novel small-molecule drugs addressing major unmet needs in cardiovascular-metabolic diseases and no
Read more →MDGLThe New Madrigal Pharmaceuticals NASDAQ: SNTA Corporate Presentation June 2016 Forward-Looking Statements Any statements made in this presentation relating to future financial or business performance, conditions, plans,
The New Madrigal Pharmaceuticals NASDAQ: SNTA Corporate Presentation June 2016 Forward-Looking Statements Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and bu
Read more →MDGLSynta Pharmaceuticals to Present at Upcoming Investor Conferences in June
Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June LEXINGTON, Mass. June 2, 2016 - Synta Pharmaceuticals Corp. ( Synta ) (NASDAQ: SNTA) today announced that Marc Schneebaum, Chief Financial Officer of Synta, will be joined by Paul Friedman, M.D., designate
Read more →MDGLThe New Madrigal Pharmaceuticals NASDAQ: SNTA | May 2016 1 Forward-Looking Statements Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends, o
The New Madrigal Pharmaceuticals NASDAQ: SNTA | May 2016 1 Forward-Looking Statements Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, incl
Read more →MDGLSynta Pharmaceuticals/Madrigal Pharmaceuticals Merger Announcement Date
Synta Pharmaceuticals/Madrigal Pharmaceuticals Merger Announcement Date: April 14, 2016 8:30 AM ET Participant Call in numbers: (855) 451-4851 (US) or (503) 343-6064 (International) Participant Passcode: 91034442 Chen Schor, President and Chief Executive Officer of Synta Ma
Read more →MDGLSynta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company Combined Company Well-Funded to Generate Data from Multiple Phase 2 Studies Paul A. Friedman, M.D. Named C
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company Combined Company Well-Funded to Generate Data from Multiple Phase 2 Studies Paul A. Friedman, M.D. Named Chairman and Chief Executive Officer of Combined Company
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Reports Third Quarter 2015 Financial Results Announces Reduction in Force, Appointment of
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Reports Third Quarter 2015 Financial Results Announces Reduction in Force, Appointment of Scott Morenstein to Board of Directors LEXINGTON,
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer Com
Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer Company to Host Conference Call on Wednesday, October 21 at 8:00 AM ET LEXINGTON, Mass. October 20, 2015 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company has
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Chen Schor Named President, Chief Executive Officer and Director
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Chen Schor Named President, Chief Executive Officer and Director LEXINGTON, Mass. April 27, 2015 Synta Pharmaceuticals Corp. (NASDAQ: SNT
Read more →MDGLSynta Pharmaceuticals Closes Public Offering of Common Stock LEXINGTON, Mass. (BUSINESS WIRE)
Synta Pharmaceuticals Closes Public Offering of Common Stock LEXINGTON, Mass. (BUSINESS WIRE) Apr. 6, 2015 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today the closing of its underwritten public offering of 25,300,000 shares of common stock, including 3,300,000 shares
Read more →MDGLSynta Pharmaceuticals Prices Public Offering of Common Stock LEXINGTON, Mass. (BUSINESS WIRE)
Synta Pharmaceuticals Prices Public Offering of Common Stock LEXINGTON, Mass. (BUSINESS WIRE) Mar. 31, 2015 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that it has priced an underwritten public offering of 22,000,000 shares of its common stock at a price to the pu
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Outlines New Corporate Strategy Strategy Aimed at Focusing Resources on Achieving Value-Cr
Synta Outlines New Corporate Strategy Strategy Aimed at Focusing Resources on Achieving Value-Creating Milestones in 2015 and 2016 LEXINGTON, Mass. (BUSINESS WIRE) February 5, 2015 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today outlined a new corporate strategy aimed at focu
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Strengthens Management Team with Two Executive Appointments -Chen Schor Named Chief Operat
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Strengthens Management Team with Two Executive Appointments -Chen Schor Named Chief Operating Officer; Marc Schneebaum Named Chief Financial
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Names Anne Whitaker Chief Executive Officer LEXINGTON, MA
Synta Names Anne Whitaker Chief Executive Officer LEXINGTON, MA August 6, 2014 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that Anne Whitaker will join the Company as President, Chief Executive Officer and a member of the Company s Board of Directors effective Sep
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Study for Patients
Synta Announces Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Study for Patients with AML and High-Risk MDS - Follows Positive Interim Analysis of Phase 2 Results - - First of Three Randomized Studies Sponsored by Cardiff University and Supported by the Leukemia
Read more →MDGLSynta Pharmaceuticals NASDAQ: SNTA GALAXY-1 Final Results
Database lock: April 2014 Population selected for Phase 3 OS: Chemosensitive Population HR, unadjusted 0.71, p = 0.023 HR, adjusted 0.69, p = 0.019 Median G+D vs. D 11.0 vs. 7.4 months Events 132 (75%) Months HR, unadjusted 0.75, p = 0.040 HR, adjusted 0.74, p = 0.042 Median G+D
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Pharmaceuticals Enters Into Agreement to Sell $5.0 Million in Common Stock Directly to an
Synta Pharmaceuticals Enters Into Agreement to Sell $5.0 Million in Common Stock Directly to an Affiliate of Synta Board Member Bruce Kovner LEXINGTON, Mass., April 14, 2014 (BUSINESS WIRE) Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the entry into a Subscription
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Positive Interim Results from the ENCHANT-1 Trial of Ganetespib in Metastatic Br
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Positive Interim Results from the ENCHANT-1 Trial of Ganetespib in Metastatic Breast Cancer at the 9th European Breast Cancer Conference
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Executive Management Changes, Appoints Dr. Paul A. Friedman Director Safi R. Bah
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Executive Management Changes, Appoints Dr. Paul A. Friedman Director Safi R. Bahcall, Ph.D., Resigns as President, CEO and Director; Ne
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Appointment of Steven Bernitz as Senior Vice President, Corporate Development LE
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Appointment of Steven Bernitz as Senior Vice President, Corporate Development LEXINGTON, MA December 20, 2013 Synta Pharmaceuticals Corp.
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 Synta Pharmaceuticals Closes Public Offering of Common Stock LEXINGTON, MA
Synta Pharmaceuticals Closes Public Offering of Common Stock LEXINGTON, MA November 18, 2013 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today the closing of its underwritten public offering of 16,100,000 shares of common stock, including 2,100,000 shares sold pursuant
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 Synta Pharmaceuticals Prices Public Offering of Common Stock LEXINGTON, MA
Synta Pharmaceuticals Prices Public Offering of Common Stock LEXINGTON, MA November 13, 2013 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that it has priced an underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $3.75 p
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Positive One-Year Follow-up Results for the GALAXY-1 Trial of Ganetespib in NSCL
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Positive One-Year Follow-up Results for the GALAXY-1 Trial of Ganetespib in NSCLC at the 2013 World Conference on Lung Cancer Res
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Fast Track Designation Granted for Ganetespib in Non-Small Cell Lung Adenocarcin
Synta Announces Fast Track Designation Granted for Ganetespib in Non-Small Cell Lung Adenocarcinoma LEXINGTON, MA September 12, 2013 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Launch of Proprietary Small Molecule Hsp90-inhibitor Drug Conjugate Platform Nov
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Launch of Proprietary Small Molecule Hsp90-inhibitor Drug Conjugate Platform Novel drug conjugates that exploit Hsp90 biology to s
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces ENCHANT-1 Breast Cancer Results Support Transition to Second Stage of Trial Tria
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces ENCHANT-1 Breast Cancer Results Support Transition to Second Stage of Trial Trial evaluating ganetespib monotherapy in HER2-positive and
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Positive Overall Survival Results From GALAXY-1 Phase 2b/3 Trial of Ganetespib i
Synta Announces Positive Overall Survival Results From GALAXY-1 Phase 2b/3 Trial of Ganetespib in Second-Line Non-Small Cell Lung Cancer Data presented at ASCO 2013 Median overall survival improved 32% in the all adenocarcinoma, intent-to-treat population In the population se
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7213 fax : 781 274 1270 www.syntapharma.com Synta Announces Appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Develo
Synta Announces Appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Development LEXINGTON, MA March 13, 2013 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the appointment of Dr. Sumant Ramachandra as President, Research and Development. Prior
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Pharmaceuticals Announces $60 Million Registered Direct Common Stock Offering LEXINGTON, M
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Pharmaceuticals Announces $60 Million Registered Direct Common Stock Offering LEXINGTON, MA December 13, 2012 Synta Pharmaceuticals Corp. (NASDAQ:
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Updated Results from Phase 2b/3 GALAXY Trial Show Promising Improvement in Survival from the Add
Updated Results from Phase 2b/3 GALAXY Trial Show Promising Improvement in Survival from the Addition of Ganetespib to Docetaxel in Second-Line Non-Small Cell Lung Cancer Data presented at ESMO 2012 Congress Results support advancing to Phase 3 stage of GALAXY trial Ganetesp
Read more →MDGLOverview We are a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and ch
We are a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. We have two drug candidates in clinical
Read more →MDGLSynta Pharmaceuticals (NASDAQ: SNTA) GALAXY Trial Interim Results June 27 2012 Conference Call Forward-looking statements This presentation may contain forward-looking statements. These statements reflect our current vie
"A Phase 1 Dose-Escalation Study of the Oral Heat Shock Protein 90 Inhibitor PF-04929113 (SNX5422) and its Associated Ocular Toxicity," AACR-EORTC-NCI Nov 2010 Pos # 375 Mahaseth et al., Antiangiogenic Effects Associated with the Inhibition of HSP90 in Colorectal Cancer, AACR 201
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Pharmaceuticals Closes Public Offering of Common Stock LEXINGTON, MA
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Pharmaceuticals Closes Public Offering of Common Stock LEXINGTON, MA January 11, 2012 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today th
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Pharmaceuticals Prices Public Offering of Common Stock LEXINGTON, MA
Synta Pharmaceuticals Prices Public Offering of Common Stock LEXINGTON, MA January 6, 2012 Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that it has priced an underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $4.40 per
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Announces Ganetespib Phase 2 Non-small Cell Lung Cancer Trial Results Show Encouraging Sin
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Announces Ganetespib Phase 2 Non-small Cell Lung Cancer Trial Results Show Encouraging Single Agent Clinical Activity - 75% of patients with ALK+
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Pharmaceuticals Announces $35 Million Registered Direct Offering of Common Stock LEXINGTON
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Pharmaceuticals Announces $35 Million Registered Direct Offering of Common Stock LEXINGTON, MA April 15, 2011 Synta Pharmaceuticals Corp. (NAS
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Announces Ganetespib Results at AACR Inhibition of Multiple Oncogenes and Resistance Mecha
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Announces Ganetespib Results at AACR Inhibition of Multiple Oncogenes and Resistance Mechanisms Leads to Potent Activity in NSCLC and Strong Enhance
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Announces Encouraging Preliminary Results for Ganetespib (STA-9090) in Phase 2 Non-small C
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Announces Encouraging Preliminary Results for Ganetespib (STA-9090) in Phase 2 Non-small Cell Lung Cancer Trial - Results demonstrate ganetes
Read more →MDGLMultiple Myeloma Research Foundation (MMRF) and Synta Pharmaceuticals Enter into Joint Collaboration to Accelerate Drug Development for Myeloma Patients Study to evaluate activity and safety of potent Hsp90 inhibitor gan
Multiple Myeloma Research Foundation (MMRF) and Synta Pharmaceuticals Enter into Joint Collaboration to Accelerate Drug Development for Myeloma Patients Study to evaluate activity and safety of potent Hsp90 inhibitor ganetespib (formerly STA-9090) as single agent and in combinat
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Pharmaceuticals Reports Sale of $5 Million in Common Stock to Member of Synta Board of Dir
Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Pharmaceuticals Reports Sale of $5 Million in Member of Synta Board of Directors LEXINGTON, MA November 11, 2010 Synta Pharmaceuticals Corp. (NA
Read more →MDGLSynta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington, MA 02421 tel: 781 541 7125 fax : 781 274 8228 www.syntapharma.com Synta Pharmaceuticals Appoints Donald Kufe, M.D. to Board of Directors LEXINGTON, MA
Synta Pharmaceuticals Appoints Donald Kufe, M.D. to Board of Directors LEXINGTON, MA September 30, Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical con
Read more →MDGLSynta Announces Expansion of Phase 2 Trial for STA-9090 in Non-Small Cell Lung Cancer Based on Encouraging Clinical Activity Trial size expanded from up to 69 patients to up to 146 patients
Expansion of Phase 2 Trial for STA-9090 in Non-Small Cell Lung Cancer Based on Encouraging Clinical Activity expanded from up to 69 patients to up to 146 patients LEXINGTON, Mass., Sep 13, 2010 (BUSINESS WIRE) Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical c
Read more →Competitive Position
How MDGL ranks across every disease it competes inCompetitive Position is a premium feature
See how MDGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial